Hira Khalid
Hira Khalid has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Javed Iqbal
Department of Chemistry, University of Sahiwal, Sahiwal, 57000, Pakistan.
3 shared publications - Muhammad Athar Abbasi
Department of Chemistry Government College University Lahore Pakistan
3 shared publications - Rashid Hussain
Forman Christian College (A Chartered University)
3 shared publications An Yang
Department of Medicinal Chemistry, University of Minnesota College of Pharmacy—Twin Cities, Minneapolis, USA
2 shared publications- Aziz- Ur- Rehman
Department of Chemistry, Government College University, Lahore 54000, Pakistan
2 shared publications - Damien M. Rasmussen
Department of Pharmacology, University of Minnesota
2 shared publications
Latest Publications
- Open Access
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (41) , 48586-48602
Computational Evaluation of Azinane–Amide-Coupled Triazoles Enabled by an Alkali Metal Reagent as Anti-Enzymatic Agents
A new electrophile was synthesized and merged with 1,2,4-triazole and piperidine to avail the aimed library of compounds, 10a i‑v and 10b i‑v . Various 4-(substituted)benzenesulfonyl chlorides (1 i‑v ) were treated with ethyl piperidin-4-carboxylate (2a) and ethyl piperidin-3-carboxylate (2b) to acquire 3a i‑v and 3b i‑v esters bearing a sulfamoyl moiety. These esters were converted to different 1,2,4-triazoles 6a i‑v and 6b i‑v through the formation of carbohydrazides and thiosemicarbazides as intermediates. A new electrophile, compound 9, was synthesized by reaction of bromoacetyl bromide (7) with an aromatic amine (8) under basic conditions. This electrophile was treated with 6a i‑v and 6b i‑v to avail the aimed library of compounds, 10a i‑v and 10b i‑v . The structural confirmation of all of the synthesized compounds was performed through 1D NMR data. The whole library of synthesized compounds was evaluated for their pharmacological potential against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), alpha glucosidase, and urease enzymes. Compound 10a iii showed better % inhibition (63.37 ± 1.25) against the AChE enzyme, while 10b i showed better % inhibition (72.38 ± 1.21) against the BChE enzyme as compared to the reference standards, Eserine and Pyridostigmine. 10b v showed best activity against the alpha-glucosidase enzyme with 64.7 ± 1.84% inhibition and the best activity against the urease enzyme was presented by compound 10b iii with the present inhibition potential of 49.3 ± 1.5. The best biofilm inhibition activity was shown by compound 10b ii with a % inhibition of 84.03141361 against bacterium, Escherichia coli. Molecular docking was performed to check the active sites of enzymes giving different values of binding affinity. The physicochemical properties and bioactivity values of synthesized compounds rendered them as active drugs. DFT was performed to study the electronic characteristics including molecular electrostatic potential (MEP), structural optimization, and HOMO–LUMO energy gap to evaluate reactivity or stability of the synthesized compounds. Furthermore, full insight evaluation may lead us to find the best antienzymatic drug candidates in the future.
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (41) , 48586-48602
Open AccessComputational Evaluation of Azinane–Amide-Coupled Triazoles Enabled by an Alkali Metal Reagent as Anti-Enzymatic Agents
A new electrophile was synthesized and merged with 1,2,4-triazole and piperidine to avail the aimed library of compounds, 10a i‑v and 10b i‑v . Various 4-(substituted)benzenesulfonyl chlorides (1 i‑v ) were treated with ethyl piperidin-4-carboxylate (2a) and ethyl piperidin-3-carboxylate (2b) to acquire 3a i‑v and 3b i‑v esters bearing a sulfamoyl moiety. These esters were converted to different 1,2,4-triazoles 6a i‑v and 6b i‑v through the formation of carbohydrazides and thiosemicarbazides as intermediates. A new electrophile, compound 9, was synthesized by reaction of bromoacetyl bromide (7) with an aromatic amine (8) under basic conditions. This electrophile was treated with 6a i‑v and 6b i‑v to avail the aimed library of compounds, 10a i‑v and 10b i‑v . The structural confirmation of all of the synthesized compounds was performed through 1D NMR data. The whole library of synthesized compounds was evaluated for their pharmacological potential against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), alpha glucosidase, and urease enzymes. Compound 10a iii showed better % inhibition (63.37 ± 1.25) against the AChE enzyme, while 10b i showed better % inhibition (72.38 ± 1.21) against the BChE enzyme as compared to the reference standards, Eserine and Pyridostigmine. 10b v showed best activity against the alpha-glucosidase enzyme with 64.7 ± 1.84% inhibition and the best activity against the urease enzyme was presented by compound 10b iii with the present inhibition potential of 49.3 ± 1.5. The best biofilm inhibition activity was shown by compound 10b ii with a % inhibition of 84.03141361 against bacterium, Escherichia coli. Molecular docking was performed to check the active sites of enzymes giving different values of binding affinity. The physicochemical properties and bioactivity values of synthesized compounds rendered them as active drugs. DFT was performed to study the electronic characteristics including molecular electrostatic potential (MEP), structural optimization, and HOMO–LUMO energy gap to evaluate reactivity or stability of the synthesized compounds. Furthermore, full insight evaluation may lead us to find the best antienzymatic drug candidates in the future.
- Open Access
- 29 September 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (39) , 45191-45203
Design, Synthesis, and Computational Studies of Novel N-(Substituted phenyl)-3-(5-((naphthalen-2-yloxy)methyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetamides as Potent Acetylcholinesterase Inhibitors
The current studies elaborate the synthesis of some new N-(substituted phenyl)-3-(5-((naphthalen-2-yloxy)methyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetamides (8a–8h). This novel synthesis was accomplished by a well-explained protocol and structural corroboration of derivatives with the help of infrared, electron ionization mass spectrometry, and 1H nuclear magnetic resonance (NMR) and 13C NMR spectral techniques. The in vitro inhibitory potential of newly synthesized acetamides was evaluated against acetylcholinesterase enzyme, and it was explored that all the compounds showed relatively comparable potential as compared to donepezil (IC50 = 0.454 ± 0.076) used as a standard. Among the unique group of these triazoles, compound 8a depicted the maximum inhibition (IC50 = 0.697 ± 0.43). With the outcomes obtained through inhibitory investigation, it was envisaged that these compounds might serve as promising acetylcholinesterase inhibitors and might also lead to a further research gateway for getting safe and nontoxic medicinal derivatives for dealing with acetylcholinesterase-related deformities. Likewise, their bioactivity results were further validated through computational density functional theory and docking analysis to develop the structure–activity relationship finding factors responsible for variable potential through engineering structures with different chemical entities.
- 29 September 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (39) , 45191-45203
Open AccessDesign, Synthesis, and Computational Studies of Novel N-(Substituted phenyl)-3-(5-((naphthalen-2-yloxy)methyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetamides as Potent Acetylcholinesterase Inhibitors
The current studies elaborate the synthesis of some new N-(substituted phenyl)-3-(5-((naphthalen-2-yloxy)methyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)acetamides (8a–8h). This novel synthesis was accomplished by a well-explained protocol and structural corroboration of derivatives with the help of infrared, electron ionization mass spectrometry, and 1H nuclear magnetic resonance (NMR) and 13C NMR spectral techniques. The in vitro inhibitory potential of newly synthesized acetamides was evaluated against acetylcholinesterase enzyme, and it was explored that all the compounds showed relatively comparable potential as compared to donepezil (IC50 = 0.454 ± 0.076) used as a standard. Among the unique group of these triazoles, compound 8a depicted the maximum inhibition (IC50 = 0.697 ± 0.43). With the outcomes obtained through inhibitory investigation, it was envisaged that these compounds might serve as promising acetylcholinesterase inhibitors and might also lead to a further research gateway for getting safe and nontoxic medicinal derivatives for dealing with acetylcholinesterase-related deformities. Likewise, their bioactivity results were further validated through computational density functional theory and docking analysis to develop the structure–activity relationship finding factors responsible for variable potential through engineering structures with different chemical entities.
- Open Access
Synthesis, characterization, and BSA binding studies of newfangled 2-phenylacetohydrazide derivatives
- Open Access
- 11 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (43) , 30052-30070
Computational medicinal chemistry applications to target Asian-prevalent strain of hepatitis C virus
Hepatitis C Virus (HCV), affecting millions of people worldwide, is the leading cause of liver disorder, cirrhosis, and hepatocellular carcinoma.
- 11 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 13 (43) , 30052-30070
Open AccessComputational medicinal chemistry applications to target Asian-prevalent strain of hepatitis C virus
Hepatitis C Virus (HCV), affecting millions of people worldwide, is the leading cause of liver disorder, cirrhosis, and hepatocellular carcinoma.
- Open Access
- 4 July 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Computational Medicinal Chemistry applications to cure Asian-prevalent strain of Hepatitis C Virus
Hepatitis C Virus (HCV), affecting millions of people worldwide, is the leading cause of the liver disorder, cirrhosis, and hepatocellular carcinoma. HCV is genetically diverse having eight gen-otypes and several subtypes predominant in different regions of the globe. The HCV NS3/4A protease is a primary therapeutic target for HCV with various FDA-approved antivirals and several clinical developments. However, available protease inhibitors (PIs) have lower potency against HCV genotype 3 (GT3), prevalent in South Asia. In this study, the incumbent computational tools were utilized to understand and explore interactions of the HCV GT3 receptor with the potential inhibitors after the virtual screening of one million compounds retrieved from the ZINC database. The molecular dynamics, pharmacological studies, and experimental studies uncovered the potential PIs as ZINC000224449889, ZINC000224374291, and ZINC000224374456 and derivative of ZINC000224374456 from the ZINC library. The study revealed that these top hit compounds exhibited good binding and better pharmacokinetics properties that might be considered the most promising compound against HCV GT3 protease. Viability test, on primary healthy Human Gingival Fibroblasts (HGFs) and cancerous AGS cell line were also performed to assess their safety profile after administration. In addition, Surface Plasmon Resonance (SPR) was also performed for determination of affinity and kinetics of synthesized compounds with target proteins.
- 4 July 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessComputational Medicinal Chemistry applications to cure Asian-prevalent strain of Hepatitis C Virus
Hepatitis C Virus (HCV), affecting millions of people worldwide, is the leading cause of the liver disorder, cirrhosis, and hepatocellular carcinoma. HCV is genetically diverse having eight gen-otypes and several subtypes predominant in different regions of the globe. The HCV NS3/4A protease is a primary therapeutic target for HCV with various FDA-approved antivirals and several clinical developments. However, available protease inhibitors (PIs) have lower potency against HCV genotype 3 (GT3), prevalent in South Asia. In this study, the incumbent computational tools were utilized to understand and explore interactions of the HCV GT3 receptor with the potential inhibitors after the virtual screening of one million compounds retrieved from the ZINC database. The molecular dynamics, pharmacological studies, and experimental studies uncovered the potential PIs as ZINC000224449889, ZINC000224374291, and ZINC000224374456 and derivative of ZINC000224374456 from the ZINC library. The study revealed that these top hit compounds exhibited good binding and better pharmacokinetics properties that might be considered the most promising compound against HCV GT3 protease. Viability test, on primary healthy Human Gingival Fibroblasts (HGFs) and cancerous AGS cell line were also performed to assess their safety profile after administration. In addition, Surface Plasmon Resonance (SPR) was also performed for determination of affinity and kinetics of synthesized compounds with target proteins.
- Open Access
- 3 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding
Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. In this paper, we describe the development and mechanism of action of type III inhibitors that bind CDK2 with nanomolar affinity. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as contraceptive agents is seen by incubation with spermatocyte chromosome spreads from mouse testicular explants, where they recapitulate Cdk2-/- and Spdya-/- phenotypes.
- 3 June 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Open AccessDevelopment of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding
Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. In this paper, we describe the development and mechanism of action of type III inhibitors that bind CDK2 with nanomolar affinity. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as contraceptive agents is seen by incubation with spermatocyte chromosome spreads from mouse testicular explants, where they recapitulate Cdk2-/- and Spdya-/- phenotypes.
- Open Access
- 26 March 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (13) , 11952-11965
Modular and Computational Access to Innocuous Multistep Metal-Free Synthesis of 1,3,4-Oxadiazoles as Enzyme Inhibitors
An array of 1,3,4-oxadiazole hybrids, 7a-s, structurally intriguing cores with potential in natural product synthesis and drug discovery, have been synthesized using innovative comparable conventional and microwave-assisted protocols. The synthesis was performed by the reaction of secondary amine-based acetamides, 6a-s, as the electrophile and piperidine-based oxadiazoles as the nucleophile, 3, under the metal-free reaction conditions. High yield in minimum time with highest purity was obtained by the microwave-irradiated method instead of the conventional one. The structural elucidations were made through infrared, 1H NMR, 13C NMR, and elemental analysis studies. The whole array of synthesized compounds, 7a-s, was evaluated for their potential against α-glucosidase and butyryl cholinesterase (BChE) enzymes. Natural bond orbital and structural optimizations were made by using the B3LYP method and the basis set of 6-311++G(d,p). Frontier molecular orbitals and molecular electrostatic potential were calculated at the same level of selected compounds as potential candidates against BChE and α-glucosidase enzymes utilizing the time-dependent density functional theory. Fifteen compounds out of 19 were observed to be active against α-glucosidase enzyme in comparison with acarbose as the reference standard and 7 against the BChE enzyme compared to eserine as the reference standard. The highest potential of compound 7j against BChE is well correlated by the higher binding interaction with target protein as -10.2, calculated by docking studies. The recruited compounds against both enzymes could be the best anti-enzymatic drugs and part of drugs discovery programs after further analysis.
- 26 March 2023
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 8 (13) , 11952-11965
Open AccessModular and Computational Access to Innocuous Multistep Metal-Free Synthesis of 1,3,4-Oxadiazoles as Enzyme Inhibitors
An array of 1,3,4-oxadiazole hybrids, 7a-s, structurally intriguing cores with potential in natural product synthesis and drug discovery, have been synthesized using innovative comparable conventional and microwave-assisted protocols. The synthesis was performed by the reaction of secondary amine-based acetamides, 6a-s, as the electrophile and piperidine-based oxadiazoles as the nucleophile, 3, under the metal-free reaction conditions. High yield in minimum time with highest purity was obtained by the microwave-irradiated method instead of the conventional one. The structural elucidations were made through infrared, 1H NMR, 13C NMR, and elemental analysis studies. The whole array of synthesized compounds, 7a-s, was evaluated for their potential against α-glucosidase and butyryl cholinesterase (BChE) enzymes. Natural bond orbital and structural optimizations were made by using the B3LYP method and the basis set of 6-311++G(d,p). Frontier molecular orbitals and molecular electrostatic potential were calculated at the same level of selected compounds as potential candidates against BChE and α-glucosidase enzymes utilizing the time-dependent density functional theory. Fifteen compounds out of 19 were observed to be active against α-glucosidase enzyme in comparison with acarbose as the reference standard and 7 against the BChE enzyme compared to eserine as the reference standard. The highest potential of compound 7j against BChE is well correlated by the higher binding interaction with target protein as -10.2, calculated by docking studies. The recruited compounds against both enzymes could be the best anti-enzymatic drugs and part of drugs discovery programs after further analysis.
- Open Access
Development of allosteric, selective cyclin-dependent kinase 2 (CDK2) inhibitors that are negatively cooperative with cyclin binding and show potential as contraceptive agents
Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. 1 However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. 1-2 In this paper, we describe the development and mechanism of action of new type III inhibitors that bind CDK2 with nanomolar affinity, making them the highest affinity, structurally confirmed allosteric CDK inhibitors reported. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as efficacious contraceptive agents is seen by incubation with mouse testicular explants, where they recapitulate Cdk2 -/- and Spdya -/- phenotypes.
Open AccessDevelopment of allosteric, selective cyclin-dependent kinase 2 (CDK2) inhibitors that are negatively cooperative with cyclin binding and show potential as contraceptive agents
Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. 1 However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. 1-2 In this paper, we describe the development and mechanism of action of new type III inhibitors that bind CDK2 with nanomolar affinity, making them the highest affinity, structurally confirmed allosteric CDK inhibitors reported. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as efficacious contraceptive agents is seen by incubation with mouse testicular explants, where they recapitulate Cdk2 -/- and Spdya -/- phenotypes.
- Open Access
- 25 March 2022
- Published by Walter de Gruyter GmbH in Pure and Applied Chemistry
- Vol. 94 (7) , 809-818
HCV genotype-specific drug discovery through structure-based virtual screening
Hepatitis C Virus (HCV) poses great threat worldwide, and is a major cause for liver cancer. HCV genome encodes polyprotein that is subsequently cleaved into independently functioning proteins, which spread viral infection in host. The Non-Structural 3 (NS3) protease is responsible for cleaving the polyprotein, and may serve as a potential drug target. Since HCV has seven genotypes, the available drugs are predominantly designed for genotype 1 (GT1), and others prevalent in Europe. Consequently, these drugs lose efficacy when they are used for different genotypes. The current perspective study aims to find potential drug candidate against genotype 3 (GT3), prevalent in South Asia. The current study employed molecular docking technique and in silico ADME prediction tool to highlight potentially active compounds against HCV NS3 GT3. The study revealed Li_PIO_114 and Li_PIH_191 as potential lead compounds, as suggested by their docking score and ADME properties. These two compounds could be further optimized to improve their drug likeliness for curing HCV GT3.
- 25 March 2022
- Published by Walter de Gruyter GmbH in Pure and Applied Chemistry
- Vol. 94 (7) , 809-818
Open AccessHCV genotype-specific drug discovery through structure-based virtual screening
Hepatitis C Virus (HCV) poses great threat worldwide, and is a major cause for liver cancer. HCV genome encodes polyprotein that is subsequently cleaved into independently functioning proteins, which spread viral infection in host. The Non-Structural 3 (NS3) protease is responsible for cleaving the polyprotein, and may serve as a potential drug target. Since HCV has seven genotypes, the available drugs are predominantly designed for genotype 1 (GT1), and others prevalent in Europe. Consequently, these drugs lose efficacy when they are used for different genotypes. The current perspective study aims to find potential drug candidate against genotype 3 (GT3), prevalent in South Asia. The current study employed molecular docking technique and in silico ADME prediction tool to highlight potentially active compounds against HCV NS3 GT3. The study revealed Li_PIO_114 and Li_PIH_191 as potential lead compounds, as suggested by their docking score and ADME properties. These two compounds could be further optimized to improve their drug likeliness for curing HCV GT3.